{"id":"brexpiprazole-adt","safety":{"commonSideEffects":[{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Restlessness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brexpiprazole modulates dopamine and serotonin neurotransmission through partial agonism at D2 and 5-HT1A receptors, which helps restore balance in neural circuits implicated in depression. When used as an adjunct to antidepressants, it enhances the therapeutic effect of standard antidepressant medications in patients with major depressive disorder who have had an inadequate response to antidepressant monotherapy.","oneSentence":"Brexpiprazole is an atypical antipsychotic that acts as a dopamine D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist, combined with adjunctive antidepressant therapy (ADT) to treat major depressive disorder.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:53.214Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment of major depressive disorder in adults with inadequate response to antidepressant monotherapy"}]},"trialDetails":[{"nctId":"NCT04830215","phase":"PHASE4","title":"Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2021-04-01","conditions":"Major Depressive Disorder","enrollment":122},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT01942733","phase":"PHASE3","title":"Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-09","conditions":"Sleep Disturbances","enrollment":44},{"nctId":"NCT01944969","phase":"PHASE3","title":"Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2013-10","conditions":"Major Depressive Disorder","enrollment":26},{"nctId":"NCT01837797","phase":"PHASE3","title":"Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2013-04","conditions":"Major Depressive Disorder","enrollment":129},{"nctId":"NCT02196506","phase":"PHASE3","title":"Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-07","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":837},{"nctId":"NCT01727726","phase":"PHASE3","title":"A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-12","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":2182},{"nctId":"NCT02400346","phase":"PHASE3","title":"Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-03","conditions":"Major Depression Disorder","enrollment":132},{"nctId":"NCT01838681","phase":"PHASE3","title":"Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-06","conditions":"Major Depressive Disorder","enrollment":1986},{"nctId":"NCT01942785","phase":"PHASE3","title":"Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-10","conditions":"Major Depressive Disorder, Irritability","enrollment":55},{"nctId":"NCT00797966","phase":"PHASE2","title":"Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":850},{"nctId":"NCT01360632","phase":"PHASE3","title":"Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-06","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":1539},{"nctId":"NCT02012218","phase":"PHASE3","title":"Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-11","conditions":"Major Depressive Disorder (MDD)","enrollment":61},{"nctId":"NCT01360645","phase":"PHASE3","title":"Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-07","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":826}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Brexpiprazole +ADT","genericName":"Brexpiprazole +ADT","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brexpiprazole is an atypical antipsychotic that acts as a dopamine D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist, combined with adjunctive antidepressant therapy (ADT) to treat major depressive disorder. Used for Adjunctive treatment of major depressive disorder in adults with inadequate response to antidepressant monotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}